Bionano Appoints Al Luderer Interim CEO Effective May 5; Twomey Lead Independent Director
Bionano Genomics appointed Board Chair Al Luderer interim president and CEO effective May 5, 2026, with Chris Twomey becoming Lead Independent Director and former CEO Erik Holmlin moving to an advisory role. Luderer has over 30 years of biotech leadership, including CEO posts at Indi Molecular, BioTrove and Light Sciences.
1. Interim Leadership Appointment
On May 5, 2026, Bionano Genomics’ Board designated Al Luderer as interim president and chief executive officer while he continues as Board Chair, and named Chris Twomey as Lead Independent Director, with outgoing CEO Erik Holmlin transitioning to an advisory capacity. The company expects the shift to occur without disrupting ongoing operations.
2. Executive Background
Dr. Al Luderer has served on Bionano’s Board since November 2011 and as Chairman since June 2024, bringing 30 years of biotechnology leadership, including CEO roles at Indi Molecular, BioTrove and Light Sciences, and senior positions in technology development, commercialization and operations at multiple life sciences firms.
3. Board Support and Search
The Board expressed confidence in Luderer’s industry expertise and institutional knowledge to maintain strategic momentum and oversee a thorough search for a permanent CEO, emphasizing continuity in advancing Bionano’s optical genome mapping solutions and commercial objectives.